isco company blog wednesday may   international stem cell corporation announces  first quarter results carlsbad ca  marketwired – may   international stem cell corporation otcqb isco wwwinternationalstemcellcom “isco” or “the company” a californiabased biotechnology company developing novel stem cellbased therapies and biomedical products today provided a business update and announced first quarter financial results for the period ended march   first quarter  business highlights ·         completed the required preclinical studies and submitted a clinical trial exemption application to the australian therapeutics goods administration tga to begin the phase a clinical study of the companys cell therapy for the treatment of parkinsons disease  to be administered through isco’s whollyowned australian subsidiary cyto therapeutics pty ltd ·         completed the manufacture of the bank of clinicalgrade human neural stem cells for use in the parkinsons disease clinical trial the cell bank contains over  billion human cells sufficient to meet the company’s foreseeable clinical trial requirements ·         japan patent office granted iscos patent covering methods of making a bank of human stem cells from parthenogenetically activated eggs significantly strengthening and expanding the company’s intellectual property to now include japan as well as the united states and the european union first quarter  financial highlights ·          million in revenue for the three months ended march   lifeline skin care sales up  and lifeline cell technology sales down   operating income from cosmeceutical and biomedical markets up  compared with the corresponding period of   gross margin improved to  ·         net loss reduced to  million for the first three months of  compared to  million for the corresponding period of   the company ended the first quarter of  with cash of  million “in the first quarter of  we completed all the necessary preclinical studies of our parkinson’s program and formally submitted our application to begin the first clinical study of this novel approach to treating this debilitating disease in humans” stated andrey semechkin phd ceo and cochairman of isco  “we continue to expect to make significant progress during the rest of  towards our goal of providing a viable treatment options for people with parkinson’s disease” about international stem cell corporation international stem cell corporation is focused on the therapeutic applications of human parthenogenetic stem cells hpscs and the development and commercialization of cellbased research and cosmetic products  iscos core technology parthenogenesis results in the creation of pluripotent human stem cells from unfertilized oocytes eggs  hpscs avoid ethical issues associated with the use or destruction of viable human embryos  isco scientists have created the first parthenogenetic homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders ages and racial background with minimal immune rejection after transplantation hpscs offer the potential to create the first true stem cell bank unistemcell™ isco also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary lifeline cell technology wwwlifelinecelltechcom and stem cellbased skin care products through its subsidiary lifeline skin care wwwlifelineskincarecom more information is available at wwwinternationalstemcellcom to subscribe to receive ongoing corporate communications please click on the following link httpwwwbiusirpassaspbzidtoeas to like our facebook page or follow us on twitter for company updates and industry related news visit wwwfacebookcominternationalstemcellcorporation and wwwtwittercomintlstemcell safe harbor statement statements pertaining to anticipated developments expected clinical studies including timing and results progress of research and development and other opportunities for the company and its subsidiaries along with other statements about the future expectations beliefs goals plans or prospects expressed by management constitute forwardlooking statements any statements that are not historical fact including but not limited to statements that contain words such as will believes plans anticipates expects estimates should also be considered to be forwardlooking statements forwardlooking statements involve risks and uncertainties including without limitation risks inherent in the development andor commercialization of potential products regulatory approvals need and ability to obtain future capital application of capital resources among competing uses and maintenance of intellectual property rights actual results may differ materially from the results anticipated in these forwardlooking statements and as such should be evaluated together with the many uncertainties that affect the companys business particularly those mentioned in the cautionary statements found in the companys securities and exchange commission filings the company disclaims any intent or obligation to update forwardlooking statements international stem cell corporation and subsidiaries condensed consolidated balance sheets in thousands except share data march  december    assets unaudited cash and cash equivalents     accounts receivable net of allowance for doubtful accounts of  at march      and december     inventory net   prepaid expenses and other current assets   restricted cash   total current assets   property and equipment net   intangible assets net   deposits and other assets   total assets     liabilities and stockholders equity deficit accounts payable     accrued liabilities   related party payable   advances   fair value of warrant liability   total current liabilities   commitments and contingencies stockholders equity deficit series b convertible preferred stock  par value  shares authorized     issued and outstanding with liquidation preferences of  and  at march      and december   respectively — — series d convertible preferred stock  par value  shares authorized  issued and    outstanding with liquidation preference of  — — series g convertible preferred stock  par value  shares authorized    issued and outstanding with liquidation preference of    series h convertible preferred stock  par value  shares authorized     and  issued and outstanding at march   and  december   respectively — — series h convertible preferred stock  par value  shares authorized issued and    outstanding — — common stock  par value  shares authorized  and     shares issued and outstanding at march   and december   respectively   additional paidin capital   accumulated deficit     total stockholders equity deficit    total liabilities and stockholders equity deficit     see accompanying notes to the unaudited condensed consolidated financial statements international stem cell corporation and subsidiaries condensed consolidated statements of operations in thousands except per share data unaudited three months ended march    revenues product sales     total revenue   expenses cost of sales   research and development   selling and marketing   general and administrative   total expenses   loss from operating activities     other income expense change in fair value of warrant liability   interest expense     sublease income   total other income net   loss before income taxes     provision for income taxes — — net loss       net loss applicable to common stockholders       net loss per common sharebasic and diluted       weighted average sharesbasic   weighted average sharesdiluted   see accompanying notes to the unaudited condensed consolidated financial statements contacts international stem cell corporation simon craw phd executive vice president of business development phone  email irintlstemcellcom media christopher r hippolyte phone  email chrishippolyterussopartnersllccom tony russo phd phone   email tonyrussorussopartnersllccom posted by simon at  am  comments email thisblogthisshare to twittershare to facebookshare to pinterest older posts home subscribe to posts atom isco web sites isco lifeline skin care lifeline cell tech blog archive ▼    ▼  may  international stem cell corporation announces  international stem cell corporation to present at  ►  april  ►  march  ►  february  ►  january  ►    ►  december  ►  november  ►  october  ►  september  ►  august  ►  july  ►  june  ►  may  ►  april  ►  march  ►  february  ►    ►  december  ►  november  ►  october  ►  september  ►  august  ►  july  ►  march  ►  february  ►    ►  october  ►  september  ►  august  ►  july  ►  june  ►  may  ►  april  ►  march  ►  february  ►    ►  december  ►  november  ►  october  ►  september  ►  august  ►  july  ►  june  ►  may  ►  april  ►  march  ►  february  ►  january  ►    ►  december  ►  november  ►  october  ►  september  ►  august  ►  july  ►  june  ►  may  ►  april  ►  march  ►  february  ►  january  ►    ►  december  ►  november  ►  october  ►  august  ►  july  ►  june  ►  may  ►  april  ►  march  ►  february  ►  january  ►    ►  november  ►  september  ►  july  ►  june  ►  may  ►  february  ►  january  ►    ►  december  ►  october  andrei semechkin   zoominfocom andrey semechkin  isco  zoominfocom andrey semechkin profiles  facebook facebookemail or phonepasswordforgot accountenglish usespañolfrançais franceالعربيةportuguês brasilitaliano한국어deutschहिन्दीmessengerfacebook litepeopleplacesgameslocationscelebritiesmarketplacegroupsrecipesmomentsinstagramaboutcreate adcreate pagedeveloperscareersprivacycookiesad choicestermssettingsactivity log facebook   insider trading  semechkin andrey  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  semechkin andrey select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing purchase  pm international stem cell corp iscoob semechkin andreychief executive officerdirector owner    indirectdirect view purchase  pm international stem cell corp iscoob semechkin andreychief executive officerdirector owner    indirectdirect view purchase  pm international stem cell corp iscoob semechkin andreychief executive officerdirector owner    indirectdirect view purchase  pm international stem cell corp iscoob semechkin andreychief executive officerdirector owner    indirectdirect view purchase  pm international stem cell corp iscoob semechkin andreychief executive officerdirector owner    indirectdirect view stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing exercise  pm  international stem cell corp iscoob semechkin andreychief executive officerdirector owner   direct view exercise  pm  international stem cell corp iscoob semechkin andreychief executive officerdirector owner   direct view exercise  pm  international stem cell corp iscoob semechkin andreychief executive officerdirector owner   direct view exercise  pm  international stem cell corp iscoob semechkin andreychief executive officerdirector owner   direct view option award  pm na international stem cell corp iscoob semechkin andreychief executive officerdirector owner   direct view purchase  pm nana international stem cell corp iscoob semechkin andreychief executive officerdirector owner   direct view purchase  pm  international stem cell corp iscoob semechkin andreychief executive officerdirector owner   direct view purchase  pm  international stem cell corp iscoob semechkin andreychief executive officerdirector owner   direct view purchase  pm  international stem cell corp iscoob semechkin andreychief executive officerdirector owner   direct view conversion  pm nana international stem cell corp iscoob semechkin andreychief executive officerdirector owner   direct view exercise  pm nana international stem cell corp iscoob semechkin andreychief executive officerdirector owner   direct view conversion  pm nana international stem cell corp iscoob semechkin andreychief executive officerdirector owner   direct view exercise  pm  international stem cell corp iscoob semechkin andreychief executive officerdirector owner   direct view conversion  pm  international stem cell corp iscoob semechkin andreychief executive officerdirector owner   direct view   secformcom all rights reserved archives        fri  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version isco insider trades for international stem cell corp bulletin investor alert new york markets close in market snapshot winners and losers expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close international stem cell corp otc isco go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus international stem cell corp market open  quotes are delayed by  min jul    pm isco quoteszigmandelayed   change   volume volume  quotes are delayed by  min quoteszigmandelayed previous close     change   day low day high    week low  week high   insider activity individual sorry there are no transactions available for this individual copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives dr andrey semechkin cochairman  chief executive officer ms sofya bakalova vice presidentlegal affairs  operations ms mahnaz ebrahimi chief financial officer  secretary dr russell kern director chief scientific officer  evp mr donald a wright cochairman mr charles j casamento independent director mr paul v maier independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york open marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest ppeople still aren’t saving for retirement — and that’s part of why myra is shutting down pto be a better investor read more good novels pact like a pro athlete the next time you ask for a pay raise pwhy gold buyers are so susceptible to fraud poil prices log biggest weekly gain of the year pgold tallies third weekly gain on north korea news weaker dollar psept wti oil climbs  cents or  to settle at bbl pwti oil ends at highest since late may up  for the week pwhat trump could do to make obamacare ‘implode’ pare you prepared for retirement  questions to ask yourself p questions to ask yourself before you buy — or sell — a house pwagerebound story takes another hit after drab eci report pstock market lower after amazon disappointment but pares losses phow a college degree is like a social security check popinion journal the trump tax reform agenda pretire early sounds great on paper but it could cost a lot p things to do in london for  or less pwho are the beneficiaries of a k if my wife and i die at the same time pcharlie gard british baby at center of controversy has died punder armours stocks low price doesnt mean it is cheap loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft board of directors  isco skip to content isco contact us blog sitemap privacy policy search for board of directors board of directors charles j casamento independent director director since  international stem cell corporation committee membership audit committee compensation committee mr casamento is currently executive director and principal of the sage group a healthcare advisory group specializing in mergers acquisitions and partnerships between biotechnology companies and pharmaceutical companies he was the president and ceo of osteologix inc a public biopharmaceutical company developing products for treating osteoporosis from  through  from  through  he served as chairman of the board president and ceo and was founder of questcor pharmaceuticals inc mr casamento formerly served as ribogene incs president ceo and chairman of the board from  through  until it merged with cypros to form questcor he was cofounder president and ceo of interneuron pharmaceuticals inc indevus a biopharmaceutical company from  until  mr casamento has also held senior management positions at genzyme corporation where he was senior vice president pharmaceuticals and biochemicals american hospital supply where he was vice president of business development and strategic planning for the critical care division johnson  johnson hoffmannlaroche inc and sandoz inc now novartis mr casamento also serves on the board of directors of kinemed inc and is a member of the fordham university science council he was formerly vice chairman of the catholic medical mission board a large international not for profit organization providing health care services to third world countries he holds a bachelors degree in pharmacy from fordham university and an mba from iona college and was originally licensed to practice pharmacy in the states of new york and new jersey russell kern phd inside director executive vice president chief scientific officer director since  dr kern was trained in medical genetics embryology and stem cell biology he holds a phd degree in human physiology from the russian academy of medical sciences and has broad expertise in neuroscience and was part of the team along with scientists from the nyu medical school that elucidated the physiological changes that occur in the brains of parkinson’s disease patients dr kern directs isco’s rd programs including stem cell derivation differentiation and the preclinical and clinical evaluation of stem cell derived cells and tissue he has developed a general method of deriving highly pure populations of neural stem cells and dopaminergic neurons from pluripotent stems cells that is novel practical and suitable for use in a clinical setting dr kern is a wellknown speaker on stem cell biology including the use of stem cells for neurology and skin regeneration he has more than  publications in the field of parkinson’s disease and stem cell biology and he is an active member of the american academy of neurology the society for neuroscience and the international society for stem cell research paul maier independent director director since  international stem cell corporation committee membership audit committee compensation committee mr maier has over  years of experience as a senior executive in biotechnology and pharmaceutical companies mr maier is currently an independent financial consultant previously mr maier was senior vice president and chief financial officer of ligand pharmaceuticals inc nasdaq lgnd a commercial stage biopharmaceutical company a position he held from  to  from  to  mr maier served as vice president finance of dfs west a division of dfs group lp a private multinational retailer from  to  mr maier was employed by icn pharmaceuticals a pharmaceutical and biotechnology research products company where he held various executive positions in finance and general management in icn as well as spi pharmaceuticals a publicly held subsidiary mr maier has served on the boards of public and private companies mr maier received an mba from harvard business school and a bs from pennsylvania state university andrey semechkin phd inside director ceo and cochairman director since  dr semechkin is a specialist in system analysis strategic planning and corporate management he is a member of the russian academy of sciences and has been deputy director of institute of system analysis since  professor semechkin was awarded the russian government award in science and technology in  and has written several scientific books he has over  years experience creating and managing businesses across different industries and scientific sectors donald wright independent director cochairman director since  international stem cell corporation committee membership audit committee compensation committee mr wright brings to international stem cell corporation over  years of experience in starting and nurturing emerging growth companies both public and private he is president and founder of everett washingtonbased confluence capital group inc wwwconfluencecapcom which provides consulting services to institutional investors debt holders and public and private companies prior to confluence capital mr wright was president and ceo of pacific aerospace  electronics inc a company he founded in  took public and ran until  under his leadership pacific aerospace grew from annual sales of approximately  million in  to over  million in  earlier mr wright was president and ceo of washingtonbased component concepts inc a company he founded in  he is the recipient of numerous business and community awards and was named one of the  fastest growing companies in washington state for   and  by deloitte  touche additionally he was recognized by deloitte  touche as one of the  fastest growing companies in the united states for   and  mr wright served as an advisory board member for central washington university’s school of business for six years and completed the ucla director training and certification program andrey semechkin  international stem cell insider transactions  tipranks go prologin  sign up follow✓get real time transactionsinsider detailsandrey semechkininternational stem cell iscoceo director ten percent ownerranked  out of  insiders on tipranksandrey semechkins performanceprofitable transactions out of  profitable transactionsaverage returnaverage return per transactioneach transaction is measured over a  year months month period and compared to no benchmarksp sectorhow are insiders ranked most profitable insider tradestock international stem cell iscotransaction type informative buydates may    todaygain see the latest stocks traded by insiders  andrey semechkins trading historybased on form  follow✓get real time transactionscompany nameinsider positionholding valuelast transactionlast transaction amountlast transaction dateiscointernational stem cellceo director ten percent ownerinformative buymay  success rate on stock out of  profitable transactions on iscoaverage profit on stockaverage return per transaction on isco  track record showingall transactionsinformative transactionsdatetransactionamountno of sharesprice per shareprofitform  may   informative buy k    mar   informative buy k    mar   informative buy k    show moresee all insider trading from today you may also likemeet our smart portfolio see what top analysts say about your stocksget a breakdown of the different strategies based on detected insider trading activityfind the best performing analyst in each sector follow them so you never miss a recommendationrelated linkshow can i benefit from insider trading see the top  corporate insiders go to hot stocks by insiders find which stocks insiders traded today become a tipranks memberget the best investing tips  hacks straight to your emailfree membershipsubmitinsider trading daily newsletterprofessional daytrading strategy based on predictive insider transactionsannual return learn more powered by international stem cell corporations cochairman and ceo andrey semechkin phd publishes letter to shareholdershomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets close in  hr  minssp  dow  nasdaq todays chartsdont get blindsided by teslas shiny new model international stem cell corporations cochairman and ceo andrey semechkin phd publishes letter to shareholdersmarketwiredjanuary  reblogsharetweetsharecarlsbad camarketwired  jan    international stem cell corporation  otcqb  isco  wwwinternationalstemcellcom a californiabased biotechnology company developing novel stem cell based therapies and biomedical products announced today that cochairman of the board and chief executive officer andrey semechkin phd has published an open letter to shareholdersthe letter provides an update on iscos research and development accomplishments future expectations and anticipated milestones along with a discussion of iscos expanded intellectual property portfolio and a summary of the companys commercial and financial performance for the first nine months of the full text of the letter can be found at httpwwwinternationalstemcellcomshareholderletterabout international stem cell corporationiscos lead indication is parkinsons disease the parkinsons disease program uses human parthenogenetic neural stem cells hpnsc a novel therapeutic cellular product derived from the companys proprietary histocompatible human pluripotent stem cells hpnsc are selfrenewing mulitpotent cells that are precursors for the major cells of the central nervous system the ability of hpnsc to i differentiate into dopaminergic da neurons and ii express neurotrophic factors such as glial derived neurotrophic factor gdnf and brain derived neurotrophic factor bdnf to protect the nigrostriatal system offers a new opportunity for the treatment of parkinsons disease especially in cases where current small molecule approaches fail to adequately control the symptomsinternational stem cell corporation is focused on the therapeutic applications of human parthenogenetic stem cells hpscs and the development and commercialization of cellbased research and cosmetic products iscos core technology parthenogenesis results in the creation of pluripotent human stem cells from unfertilized oocytes eggs hence avoiding ethical issues associated with the use or destruction of viable human embryos isco scientists have created the first parthenogenetic homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders ages and racial background with minimal immune rejection after transplantation hpscs offer the potential to create the first true stem cell bank unistemcelltm isco also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary lifeline cell technology wwwlifelinecelltechcom and stem cellbased skin care products through its subsidiary lifeline skin care wwwlifelineskincarecom more information is available at wwwinternationalstemcellcomto receive ongoing corporate communications via email visit httpwwwbiusirpassaspbzidtoeasto like our facebook page or follow us on twitter for company updates and industry related news visit wwwfacebookcominternationalstemcellcorporation and wwwtwittercomintlstemcellforwardlooking statementsstatements pertaining to anticipated developments the potential benefits of research programs and products the plans and anticipated results of product development initiatives anticipated regulatory actions and other opportunities for the company and its subsidiaries along with other statements about the future expectations beliefs goals plans or prospects expressed by management constitute forwardlooking statements any statements that are not historical fact including but not limited to statements that contain words such as will believes plans anticipates expects estimates should also be considered to be forwardlooking statements forwardlooking statements involve risks and uncertainties including without limitation risks inherent in the development andor commercialization of potential products regulatory approvals need and ability to obtain future capital application of capital resources among competing uses and maintenance of intellectual property rights actual results may differ materially from the results anticipated in these forwardlooking statements and as such should be evaluated together with the many uncertainties that affect the companys business particularly those mentioned in the cautionary statements found in the companys securities and exchange commission filings the company disclaims any intent or obligation to update forwardlooking statementsreblogsharetweetsharerecently viewedyour list is emptywhat to read nextthe two pizza rule is a secret to productive meetings that helped amazon ceo jeff bezos become one of the worlds richest menbusiness insiderthis will be in everyones household by banyan hillsponsoredthe real reason overseas manufacturing is coming to americayahoo financetax cuts just got more likelyyahoo financechevron and exxon mobil have a tough path ahead nyse traderyahoo finance videoengineer finds pattern makes millions in stocksmoney morningsponsoredfast food restaurants work face rising wage pressuresyahoo financetodays charts dont get blindsided by teslas shiny new model yahoo financetrump’s unwitting legacy could be universal health coverageyahoo financezuckerberg wifes ambitious secret finally exposedunewzmesponsored ways to break free from your credit card debtyahoo financemy bullish view on stocks hasnt changed one iota nyse traderyahoo finance videohow a oneofakind business has kept  kitchens out of landfillsyahoo financediscover it  out of  avg by k customersdiscover cardsponsoredthe  most profitable markets for home sellerscreditcomthe government cant help people from making the singlebiggest investing mistakeyahoo financethe real reason overseas manufacturing is coming to americaed b how come we never heard about manufacturing jobs coming back to the us when obama was president especially since its been happening for years as this journalist statesjoin the conversation